Boulder, Colorado - December 16, 2008 - Bolder BioTechnology, Inc. today announced that it has been awarded a $1.9 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant will be used to perform additional preclinical toxicology and…
Read more
Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
Boulder, Colorado - October 15, 2008 - Bolder BioTechnology, Inc. announced today that it has been awarded a $1.6 million Phase II Continuing Renewal Small Business Innovation Research (SBIR) grant, entitled “Long-Acting Beta Interferon for Multiple Sclerosis”, from the National Institute of Neurological Disorders and Stroke (NINDS) of The National Institutes of Health (NIH). Receipt of…
Read more
Bolder BioTechnology Awarded NIH Grant to Continue Development of Novel Arthritis Treatment
Boulder, Colorado - August 24, 2007 - Bolder BioTechnology, Inc. today announced that it has been awarded a $685,984 Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of The National Institutes of Health. The grant provides funds to continue research to optimize a human protein…
Read more
Bolder BioTechnology Receives U.S. Patent for Second Generation Interleukin-11 Analog
Boulder, Colorado - August 23, 2007 - Bolder BioTechnology, Inc. is pleased to announce that it has been granted patent 7,253,267 by the U.S. Patent and Trademark Office. Joe Cox, Company President commented “This patent provides key intellectual property protection for our long-acting, second generation interleukin-11 (IL-11) analog product. IL-11 is a human protein that stimulates…
Read more